Real Talk Capital’s Gilead Sciences GILD Stock Holding History

Real Talk Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,356	Closed	-$328K	–	104
2026 Q1	$328K	Sell	2,356 -86	-4%	-$12K	0.31%	66
2025 Q4	$300K	Buy	+2,442	New	+$297K	0.3%	73

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Real Talk Capital's GILD Position: Q2 2026 in Review

Real Talk Capital sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 2,356 shares — an estimated $328K sold.

Real Talk Capital first reported a position in GILD in Q4 2025 and held it in 2 quarters. The position peaked at $328K in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Real Talk Capital reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
Real Talk Capital sold 2,356 Gilead Sciences shares in Q2 2026, an estimated $328K.
Real Talk Capital first reported a position in Gilead Sciences in Q4 2025 and held it in 2 quarters.
Real Talk Capital's Gilead Sciences position peaked at $328K in Q1 2026.
2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Real Talk Capital's 13F filing for Q2 2026, filed 14 Aug 2026.